These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30555156)

  • 21. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
    Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
    Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
    Bhat R; Thangavel H; Abdulkareem NM; Vasaikar S; De Angelis C; Bae L; Cataldo ML; Nanda S; Fu X; Zhang B; Schiff R; Trivedi MV
    Sci Rep; 2022 Feb; 12(1):1972. PubMed ID: 35121782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
    Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.
    Young OE; Renshaw L; Macaskill EJ; White S; Faratian D; Thomas JS; Dixon JM
    Eur J Cancer; 2008 Feb; 44(3):391-9. PubMed ID: 18083023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD).
    Dong J; Wang TL; Lu J; Ding CZ; Hu L; Hu G; He H; Zeng X; Li X; Sun D; Zhu Y; Shen L; Gu Q; Chan CC; Xia Y; Li J; Chen S
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127601. PubMed ID: 33035677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
    D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
    Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
    Xiong R; Zhao J; Gutgesell LM; Wang Y; Lee S; Karumudi B; Zhao H; Lu Y; Tonetti DA; Thatcher GR
    J Med Chem; 2017 Feb; 60(4):1325-1342. PubMed ID: 28117994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
    Wardell SE; Yllanes AP; Chao CA; Bae Y; Andreano KJ; Desautels TK; Heetderks KA; Blitzer JT; Norris JD; McDonnell DP
    Breast Cancer Res Treat; 2020 Jan; 179(1):67-77. PubMed ID: 31562570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
    Garner F; Shomali M; Paquin D; Lyttle CR; Hattersley G
    Anticancer Drugs; 2015 Oct; 26(9):948-56. PubMed ID: 26164151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.
    Zhou F; Yang G; Xue L; Liu Y; Guo Y; Zhu J; Yuan L; Gu P; Tang F; Shan J; Tang R
    Breast Cancer Res; 2023 Aug; 25(1):96. PubMed ID: 37580832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Kaminska K; Akrap N; Staaf J; Alves CL; Ehinger A; Ebbesson A; Hedenfalk I; Beumers L; Veerla S; Harbst K; Ehmsen S; Borgquist S; Borg Å; Pérez-Fidalgo A; Ditzel HJ; Bosch A; Honeth G
    Breast Cancer Res; 2021 Feb; 23(1):26. PubMed ID: 33602273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.